This Blockbuster Drug Just Got Better

The following video is part of our "Motley Fool Conversations" series, in which health-care editor and analyst David Williamson and consumer goods editor and analyst Austin Smith discuss topics across the investing world.

The roller coaster ride for best-in-class multiple sclerosis drug Tysabri looks like it is coming to a satisfying conclusion for investors, and for about half the population struggling with MS. David and Austin discuss how a new test has changed the fortune of this drug, and its makers, in this video.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time thisarticle was published Austin Smith owns shares of Pfizer. David Williamson owns shares of Pfizer. The Motley Fool owns shares of Teva Pharmaceutical Industries.Motley Fool newsletter services recommendQuest Diagnostics, Elan, Pfizer and Teva Pharmaceutical Industries. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.